News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3125last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Motley Fool128d agobullish
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?24/7 Wall St.131d agoneutral
AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech OpportunityMotley Fool136d agobullish
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider BuyingSimply Wall St.148d agoneutral
Recursion Pharmaceuticals (RXRX) Stock Valuation After AI Drug Discovery And REC-1245 REC-4881 UpdatesSimply Wall St.157d agoneutral
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 ResultsSimply Wall St.157d agoneutral
Recursion’s AI Drug Pipeline Progress Tests Investor Patience And ValuationMotley Fool159d agobullish
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?BioPharma Dive165d agoneutral
Verge, following trial failure, rebrands its AI drug discovery ambitionsMotley Fool167d agobullish
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?Insider Monkey168d agoneutral
Recursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?Simply Wall St.169d agoneutral
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Mixed Signals Emerge On Future Growth ProspectsInsider Monkey178d agobullish
Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy NowSimply Wall St.184d agoneutral
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Clinical Updates And FDA DiscussionsSimply Wall St.184d agoneutral
Recursion Milestones Link AI Discovery To Clinical And Valuation Upside